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OBJECTIVES: Ischemic stroke (IS) or transient ischemic attack (TIA) history is present in 4-17% of patients with
coronary artery disease (CAD). This subgroup of patients is at high risk for both ischemic and bleeding events.
The aim of this study was to determine the role of platelet aggregability, coagulation and endogenous
fibrinolysis in patients with CAD and previous IS or TIA.
METHODS: A prospective case-control study that included 140 stable CAD patients divided into two groups: the
CASE group (those with a previous IS/TIA, n=70) and the CONTROL group (those without a previous IS/TIA,
n=70). Platelet aggregability (VerifyNow Aspirins and VerifyNow P2Y12s), coagulation (fibrinogen and
thromboelastography by Reoroxs) and endogenous fibrinolysis (D dimer and plasminogen activator inhibitor-1)
were evaluated.
RESULTS: Patients in the CASE group presented significantly higher systolic blood pressure levels (135.84±16.09
vs 123.68±16.11, po0.01), significantly more previous CABG (25.71% vs 10%, p=0.015) and significantly higher
calcium channel blocker usage (42.86% vs 24.29%, p=0.02) than those in the control group. In the adjusted
models, low triglyceride values, low hemoglobin values and higher systolic blood pressure were significantly
associated with previous IS/TIA (CASE group). Most importantly, platelet aggregability, coagulation and
fibrinolysis tests were not independently associated with previous cerebrovascular ischemic events (CASE
group).
CONCLUSION: Platelet aggregability, coagulation and endogenous fibrinolysis showed similar results among
CAD patients with and without previous IS/TIA. Therefore, it remains necessary to identify other targets to
explain the higher bleeding risk presented by these patients.
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’ INTRODUCTION
Ischemic stroke (IS) or transient ischemic attack (TIA)
history is present in approximately 4-8% (1-3) of patients with
acute coronary syndrome (ACS) and approximately 4-17% of
patients with stable atherosclerotic disease (CAD) (4-6).
This patient population has a higher prevalence of cardio-
vascular risk factors and a higher prevalence of established
cardiovascular disease compared to patients without pre-
vious ischemic cerebrovascular events (IS/TIA). These
characteristics imply a high risk for major cardiovascular
events, including cardiovascular mortality (4-7).
On the other hand, patients with previous IS/TIA also have
an increased incidence of major bleeding events, especially
when subjected to the more potent modern antithrombotic
regimens, which include some of the new antiplatelet drugs
that are contraindicated in this population (8-10).
Platelet aggregability, the coagulation system and endo-
genous fibrinolysis play key roles in the "ischemic-hemor-
rhagic" balance. However, little is known about the roles of
these factors specifically in patients with prior cerebrovas-
cular events.
The purpose of this study was to evaluate whether
patients with CAD and previous IS/TIA show any differ-
ences in terms of platelet aggregation, coagulation tests orDOI: 10.6061/clinics/2019/e1222
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endogenous fibrinolysis in comparison with patients without
these complications, which could explain, at least in part, the
increased bleeding risk in these individuals.
’ METHODS
Study design: This study was designed as a case-control
study (with a 1:1 allocation ratio). Individuals in the case (those
with a previous IS/TIA) and control groups were retro-
spectively selected and matched for sex, age, type of previous
ACS (STEMI, NSTEMI and UA), and time between the ACS
and inclusion in the study. Ethics approval was obtained from
the local institutional review board.
Inclusion criteria: The inclusion criteria included a prior
ACS (over 12 months prior to inclusion), a history of IS/TIA
prior to the diagnosis of ACS, chronic use of aspirin since the
diagnosis of ACS, and signing of the inform consent form.
Exclusion criteria: The exclusion criteria included a prior
hemorrhagic stroke, current dual antiplatelet therapy or anti-
inflammatory nonsteroidal therapy, any thrombophilia or
coagulopathy, thrombocytopenia (o100,000/mm3), throm-
bocytosis (4450,000/mm3), PCI or CABG in the last 6 months,
severe renal impairment (GFR o30 mL/min by MDRD) and
any terminal illness.
Participants: The medical records of all patients who were
diagnosed with ACS and had a history of IS/TIA, which
were included in the coronary care unit and cardiac surgery
service databanks, were analyzed. From January 2013 to April
2015, 918 records were evaluated; 412 did not meet the
inclusion criteria (mainly because the IS/TIA occurred after
the ACS diagnosis), 122 presented at least one of the exclusion
criteria (mainly severe kidney dysfunction), and 314 were
excluded for other reasons (mainly for the difficulty in finding
a suitable matched control subject). As shown in Figure 1, 140
individuals were included in the present study, of whom
70 were in the case group and 70 were in the control group.
Interventions: After the careful review of medical records
and confirmation of inclusion and exclusion criteria, eligible
patients were invited to participate in the study. After signing
the informed consent form, patients underwent a clinical
evaluation to confirm the data records and adherence to AAS.
Laboratory tests: In addition to hematological (CBC) and
metabolic (renal function, lipid and glucose profile) evalua-
tions, laboratory tests directly related to the main purpose of
this study were performed as follows:
 Platelet aggregability - platelet aggregation mediated by thro-
mboxane A2 (TX A2) was assessed by VerifyNow Aspirins,
while platelet aggregation mediated by ADP was evaluated
by VerifyNow P2Y12s. The high residual platelet reactivity
(HRPR) to AAS was defined by an ARU 4550 (11).
 Coagulation – fibrinogen and thromboelastography (Reoroxs)
were evaluated.
 Endogenous fibrinolysis - D dimer and plasminogen
activator inhibitor-1 (PAI-1) were evaluated.
Statistical analysis
Data normality was tested by the Kolmogorov-Smirnov
test. Continuous variables are expressed as the mean (+/- SD).
Comparisons between the two groups were performed using
Student’s t-test for Gaussian variables and the Mann-Whitney
U test for non-Gaussian variables.
Figure 1 - Inclusion Flowchart. ACS- acute coronary syndrome, IS- ischemic stroke, TIA- transient ischemic attack, GFR- glomerular
filtration rate, pts- patients.
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Categorical variables are expressed as the absolute number
and relative frequency, and comparisons between the two
groups were performed using the Chi-square test or Fisher’s
exact test, as indicated.
Multivariable models
In stepwise logistic regression analysis, previous IS/TIA
was the dependent variable, and the baseline variables depic-
ted in Table 1 were the independent variables. Each of the
platelet, coagulation and endogenous fibrinolysis tests was
separately included as an independent variable, thus produ-
cing a total of 6 adjusted models.
SPSS version 20.0 software (IBM, USA) was utilized for the
analyses, and a p-valueo0.05 (2-tailed) was used to indicate
statistically significant differences. With respect to missing
data, we use a listwise deletion approach.
’ RESULTS
Study population
Of the total 140 patients included in the analyses, 70%
were male, 68% had a previous AMI, and the index ACS
occurred 5 years before inclusion in the study. Furthermore,
the mean age of the patients was 60 years.
Table 1 - Baseline characteristics of the population.
Case Group Control Group 95% CI p
Age (years ±SD) 67.64±9.62 66.50±9.97 (-4.42; 2.13) 0.49
Male (%) 71.43 68.57 (-18.03; 12.32) 0.71
White (%) 60 47.14 (-3.53; 29.24) 0.12
BMI (kg/m2±SD) 27.86±5.6 27.47±4.46 (-1.33; 2.11) 0.65
HR (bpm±SD) 64.28±8.83 65.91±8.83 (-4.73; 1.46) 0.29
SBP (mmHg±SD) 135.84±16.09 123.68±16.11 (6.19; 18.14) o0.001
DBP (mmHg±SD) 77.03±10.99 75.66±9.26 (-2.07; 4.80) 0.43
Diabetes (%) 48.57 44.29 (-12.22; 20.79) 0.61
Hypertension (%) 94.29 85.71 (-1.27; 18.41) 0.09
Antihypertensive medications (n±SD) 2.37±1.09 3.0±1.23 (-1,02; -0,24) 0.006
CKD (%) 52.86 37.14 (-0.56; 31.99) 0.61
Hypercholesterolemia (%) 70 80 (-24.25; 4.25) 0.17
Current smoker (%) 5.71 5.71 (-7.69; 7.69) 1.00
Atrial fibrillation (%) 7.14 2.86 (-2.90; 11.47) 0.44
PAD (%) 2.86 5.71 (-9.55; 3.84) 0.68
AMI (%) 67.15 70 (-18.23; 12.52) 0.51
Time since ACS (years±SD) 5.57±2.78 5.05±2.67 (-0.40; 1.43) 0.27
PCI (%) 31.43 31.43 (-15.38; 15.38) 1.00
CABG (%) 25.71 10 (3.30; 28.13) 0.015
Medications
Aspirin 4100 mg/d (%) 11.42 8.57 (-7.07; 12.78) 0.57
Statin (%) 94.29 94.29 (-7.69; 7.69) 1.00
ACE inhibitor (%) 54.29 57.14 (-19.31; 13.59) 0.73
ARB (%) 27.14 18.57 (-5.27; 22.41) 0.22
Calcium channel blocker (%) 42.86 24.29 (3.23; 33.91) 0.02
Diuretics (%) 44.29 37.14 (-9.09; 23.38) 0.38
Nitrate (%) 28.57 15.71 (-0.73; 26.45) 0.06
Beta blocker (%) 88.57 80.00 (-3.40; 20.54) 0.16
Oral hypoglycemic medications (%) 41.43 44.29 (-19.25; 13.53) 0.73
Insulin (%) 10.00 18.57 (-20.08; 2.93) 0.14
PPI (%) 61.43 42.86 (2.31; 34.83) 0.07
Oral anticoagulants (%) 7.14 2.86 (-2.90; 1.47) 0.44
SRI (%) 12.86 7.14 (-4.18; 15.61) 0.25
Hematologic, metabolic and inflammatory tests
Hemoglobin (g/dL) 14.18±1.63 14.59±1.40 (-0.93; 0.09) 0.10
Platelets/mm3 242228.6±62225.98 237857.1±56653.1 (-16411; 25154) 0.67
Leukocytes/mm3 7468.29±1882.81 7647.57±1961.47 (-821.80; 463.28) 0.58
Total cholesterol (mg/dL) 162.56±38.86 165.61±38.44 (-15.98; 9.86) 0.64
LDL (mg/dL) 92.39±30.01 93.23±31.51 (-11.13; 9.44) 0.87
HDL (mg/dL) 43.37±13.2 44.31±9.93 (-4.85; 2.96) 0.63
Triglycerides (mg/dL) 133.00±59.57 144.46±95.69 (-38.10; 15.18) 0.90
BUN (mg/dL) 44.26±14.03 41.46±15.17 (-2.08; 7.68) 0.09
Creatinine (mg/dL) 1.24±0.35 1.11±0.27 (0.02; 0.23) 0.037
GFR (mL/min/1.73 m2) 66.03±22.61 68.48±21.54 (-9.88; 4.98) 0.35
Fasting glucose (mg/dL) 116.16±32.03 134.88±57.58 (-62.49; -2.32) 0.031
HBA1c (%) 7.57±8.74 7.05±2.17 (-1.61; 2.65) 0.63
Lipoprotein (a) 47.39±43.81 44.14±44.78 (-11.73; 18.23) 0.55
us-CRP (mg/dL) 5.41±7.95 3.79±5.25 (-0.63; 3.88) 0.06
INR 1.07±0.21 1.08±0.31 (-0.098; 0.078) 0.36
BMI- body mass index, HR- heart rate, SBP- systolic blood pressure, DBP- diastolic blood pressure, CKD- chronic kidney disease, PAD- peripheral artery
disease, AMI- acute myocardial infarction, PCI- percutaneous coronary intervention, CABG- coronary artery bypass graft, ACE- angiotensin-converting
enzyme, ARB- angiotensin receptor blocker, PPI- proton-pump inhibitors, SRI- serotonin receptor inhibitors, LDL- low-density lipoprotein cholesterol,
HDL- high-density lipoprotein cholesterol, BUN- blood urea nitrogen, GFR- glomerular filtration rate, HBA1c- glycated hemoglobin, us-CRP- ultra sensitive
C-reactive protein, INR- international normalized ratio, 95% CI- 95% confidence interval.
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Baseline characteristics
As shown in Table 1, patients in the case and control
groups were adequately matched for the prespecified varia-
bles. However, patients in the case group presented signifi-
cantly higher systolic blood pressure levels (135.84±16.09 vs
123.68±16.11, po0.001), even though the use of antihyper-
tensive medications was more common in this population
(2.37±1.09 vs 3.0±1.23, p=0.006).
Cardiologic risk factors in both groups did not show statis-
tically significant differences. In the analysis of preexisting
cardiovascular diseases, there were no significant differences
between the two groups with regard to AF, PAD and pre-
vious PCI. However, the case group more frequently had a
past history of CABG (25.71% vs 10%, p=0.015).
All patients were taking aspirin, as this was mandatory for
participation in the study. Few individuals were using a
dosage higher than 100 mg/day. There were no statistically
significant differences regarding previous medication usage,
except for calcium channel blockers, which were more
frequently used in the case group (42.86% vs 24.29%, p=0.02).
The values for hematological and inflammatory variables
were similar between patients in both groups. In relation to
the metabolic profile, the lipid profile did not present any
differences between the two groups. However, the case
group presented higher creatinine levels (but similar values
for the glomerular filtration rate) and higher fasting glucose
levels (although similar glycosylated hemoglobin levels)
compared to the control group.
Platelet aggregability
Platelet aggregation mediated by thromboxane A2, which
was evaluated by VerifyNows Aspirin, was not statistically
significantly different between the groups. Furthermore, this
same pattern was observed for the platelet aggregation medi-
ated by ADP, which was evaluated by VerifyNow P2Y12s.
Upon analyzing the high residual platelet reactivity to AAS,
no significant differences were again observed between the
two groups (Table 2).
Coagulation
The fibrinogen values of the case and control groups were
not statistically significantly different, and a similar pattern
was observed for the maximum clot firmness, which was
evaluated by thromboelastography (Table 2).
Endogenous fibrinolysis
No statistically significant differences were observed in
either the D dimer or PAI-1 levels (Table 2).
Adjusted models
Table 3 shows the variables that were observed as being
significantly associated with a previous IS/TIA in each of the
adjusted models. The triglyceride values were associated
with a previous IS/TIA in model 1 (including VerifyNow
Aspirin), model 2 (including VerifyNow P2Y12) and model 5
(including PAI-1). Hemoglobin values were also significantly
associated with a previous IS/TIA in 2 of the models (models
2 and 5). In model 4 (including maximum clot firmness by
thromboelastography), systolic blood pressure was asso-
ciated with a previous IS/TIA. As shown in Table 3, none of
the variables in models 3 and 6 (which included fibrinogen
and D-dimer, respectively) were associated with a previous
IS/TIA. The most important finding was that none of the
platelet aggregability, coagulation or fibrinolysis tests were
independently associated with a previous cerebrovascular
ischemic event.
’ DISCUSSION
The main finding of our study is that the higher bleeding
risk related to patients with CAD and previous cerebrovas-
cular ischemic events could not be explained by differences
Table 3 - Variables that correlated significantly and
independently with previous IS/AIT in each of the adjusted
statistical models.
Adjusted Model Variables p OR 95% CI
Model 1
Triglycerides 0.02 0.98 0.97-0.99
Model 2
Triglycerides 0.01 0.98 0.96-0.99
Hemoglobin 0.04 0.35 0.12-0.95
Model 3
N.V N.V N.V N.V
Model 4
SBP 0.03 2.69 1.05-6.8
DBP 0.04 0.36 0.13-0.98
Model 5
Triglycerides 0.03 0.98 0.97-0.99
Hemoglobin 0.03 0.11 0.01-0.87
Model 6
N.V N.V N.V N.V
Model 1- includes VerifyNow Aspirins, Model 2- includes VerifyNow
P2Y12s, Model 3- includes fibrinogen, Model 4- includes the maximum
clot firmness by thromboelastogram, Model 5- includes PAI-1, Model 6-
includes D-dimer, N.V- no statistically significant variables in the adjusted
model, SBP- systolic blood pressure, DBP- diastolic blood pressure, 95% CI-
95% confidence interval.
Table 2 - Platelet aggregation, coagulation and endogenous fibrinolysis.
Case Group Control Group 95% CI p
Platelet aggregation mediated by thromboxane A2
VerifyNow Aspirins (ARU±SD) 525.00±79.78 530.35±83.81 (-32.9; 22.2) 0.7
HRPR to AAS (%) 40.58 42.03 (-0.15; 0.17) 0.86
Platelet aggregation mediated by ADP
VerifyNow P2Y12s (PRU±SD) 262.14±43.03 251.74±43.72 (-6.16; 26.97) 0.21
Coagulation
Fibrinogen (mg/dL±SD) 370.46±80.11 366. 86±94.19 (-25.62; 32.82) 0.8
MCF (Pa±SD) 2136.00±569.97 2001.27±635.68 (-67.87; 337.33) 0.19
Endogenous fibrinolysis
D dimer (ng/dL±SD) 645.29±1321.84 459.24±769.54 (-175.40; 547.52) 0.72
PAI-1 (pg/mL±SD) 31.78±30.53 27.42±20.13 (-4.40; 13.13) 0.73
ARU- aspirin reaction units, HRPR- high residual platelet reactivity, ADP- adenosine diphosphate, PRU- P2Y12 reaction units, MCF- maximum clot firmness,
PAI-1- plasminogen activator inhibitor, SD- standard deviation, 95% CI- 95% confidence interval.
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in platelet aggregability, coagulation or endogenous fibrino-
lysis in these patients.
The ADAPT-DES study showed that HRPR to AAS
(ARU4550) is a protective factor of major bleeding after
drug-eluted stent implantation. In our patient population,
HRPR to AAS was similar among patients with previous IS/
TIA and those without previous IS/TIA, which does not
justify the difference in bleeding risk between these groups of
individuals (12).
An exacerbated response to clopidogrel (PRUo95) was
associated with higher major bleeding rates in patients inclu-
ded in the ADAPT-DES study. In our study, there were no
significant differences observed in the VerifyNow P2Y12s
results between patients in the IS/TIA and non-IS/TIA
groups who did not utilize clopidogrel. Despite the fact that
we did not analyze the eventual antiplatelet response to clo-
pidogrel, the subanalysis of the POPULAR Trial did this,
analyzing patients with and without previous IS/TIA, and
the results indicated that there were no significant differences
in the PRU after clopidogrel use between the groups (13).
It is important to remember that many medications used in
ACS treatment influence coagulation factors, which can lead
to different bleeding outcomes. Moreover, there seems to be a
stronger correlation between serum coagulation factor values
and ischemic events than between serum coagulation factor
values and bleeding events. At this moment, the only co-
agulation factor that is clearly associated with a higher
incidence of bleeding outcomes is Factor XIII, which was not
measured in our study (14).
Although endogenous fibrinolysis is an opposite process
to that of atherothrombosis, the correlation between serum
values of fibrinolysis markers and ischemic or bleeding
events is not clear. In this study, we observed no significant
differences in the analyzed groups regarding PAI-1 and D
dimer values. This finding suggests that fibrinolysis (at least
when measured by the PAI-1 and D dimer values) does not
justify the higher bleeding outcomes observed in patients
with a previous IS/TIA (15).
Three of the adjusted models used in our study suggested
a relationship between low triglyceride levels and a previous
IS/TIA. After corroborating our findings with those of the
Rotterdam study, a strong correlation between low triglycer-
ide levels and intracerebral hemorrhage was observed (16).
In another study, Bonaventura and Cols observed a risk for
hemorrhagic stroke in patients with low triglyceride levels
(o0.94 mmol/L) that was twice as high as the risk for hemor-
rhagic stroke in those without low triglyceride levels (17).
There are some possible explanations for these findings.
First, some studies have suggested a positive relationship
between high triglyceride levels, coagulation factors and
blood viscosity, resulting in a possible prohemorrhagic state
in patients with low triglyceride values (16,18). Second, chole-
sterol and fatty acids are essential elements of cell membranes.
Experimental studies have suggested a relationship between
low cholesterol levels, higher cellular membrane permeability
(19) and endothelial weakness in small intracerebral arteries
(20). However, the influence of triglyceride levels in this
scenario has not been well studied.
Hypertension is an important risk factor for ischemic
events, including IS/TIA (21). However, hypertension is
correlated with bleeding events, especially during antith-
rombotic treatment (22). In our study, patients with previous
cerebrovascular ischemic events presented higher systolic
arterial blood pressure values at baseline despite using more
anti-hypertensive medications. These findings suggest a
difficulty in controlling systolic hypertension among patients
with a previous IS/TIA, which could be related to the higher
risk for adverse events in this population.
A low hemoglobin value is a strong predictor of major
bleeding events in patients with ACS in the intrahospital
phase and long-term follow-up phase (23-26). In our study,
low hemoglobin values were independently associated with
a previous IS/TIA (individuals at a high risk for bleeding).
In addition to being a possible marker for patients suffering
from a previous hemorrhage (e.g., gastrointestinal bleedings),
hemoglobin is directly associated with primary hemostasis
via platelet adhesion, activation and aggregability (27-30).
In summary, the higher risk for bleeding demonstrated
among patients with IS/TIA when subjected to more potent
anti-thrombotic therapies could not be explained by the
variables analyzed in this present study. Therefore, other
pathophysiologic mechanisms should be responsible for
these findings, as the presence of a dysfunctional hematoen-
cephalic barrier has been demonstrated in individuals with
previous cerebrovascular events (31-33).
Our study has some limitations. First, it has a retrospective
design. Therefore, despite having case-control matched for 4
different variables, other nonmatched variables could have
influenced the results. However, because of the low incidence
of a previous IS/TIA in patients with ACS, a prospective
design would be unpractical. Second, the case group pre-
sented with mild sequelae (mean modified Rankin scale
score=2), which may be justified by the worse outcome of
patients with higher Rankin scores. Therefore, no conclusion
can be drawn for patients with more severe sequelae post-
IS/TIA.
’ CONCLUSIONS
Platelet aggregability, coagulation and endogenous fibri-
nolysis showed similar results among CAD patients with
and without previous IS/TIA. Therefore, it remains neces-
sary to identify other targets to explain the higher bleeding
risk presented by these patients.
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